Roche said it plans to invest up to $550 million in its diagnostics site in Indianapolis by 2030. The site will become a major hub for the manufacturing of Roche's continuous glucose monitoring (CGM) systems.
Indianapolis serves as the North American headquarters for Roche Diagnostics, part of the Roche Group. The Indianapolis campus houses key operations, including U.S. research and development, laboratories, manufacturing, distribution, IT and administrative functions. It currently produces approximately 5.2 billion Accu-Chek diabetes test strips annually and serves as one of two global distribution hubs focused on serving the U.S. market and supporting distribution to 53 countries worldwide.
The expansion is expected to generate hundreds of manufacturing jobs and thousands of construction jobs. It will also enhance domestic production capabilities and reduce dependency on imports.
